Gilead appoints Dietmar Berger
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...
In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
Zacks.com on MSN1d
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItGilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion ...
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...
Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback